IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-one research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $294.21.
Several analysts have recently weighed in on the stock. Deutsche Bank Aktiengesellschaft decreased their price target on shares of IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Truist Financial lifted their target price on IQVIA from $329.00 to $346.00 and gave the company a "buy" rating in a research report on Wednesday, October 28th. UBS Group began coverage on IQVIA in a research report on Wednesday, September 30th. They set a "buy" rating and a $345.00 target price on the stock. Leerink Partners raised their target price on shares of IQVIA from $280.00 to $310.00 and gave the stock an "outperform" rating in a report on Thursday, October 8th. Finally, Weiss Ratings downgraded IQVIA from a "hold (c+)" rating to a "sell (d+)" rating in a report on Wednesday, October 28th.
View Our Latest Report on IQV
Insider Buying and Selling
In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company's stock, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.70% of the company's stock.
Hedge Funds Weigh In On IQVIA
Hedge funds have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in IQVIA in the second quarter valued at about $2,811,292,000. Dimensional Fund Advisors LP raised its holdings in IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company's stock valued at $282,657,000 after acquiring an additional 66,643 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in IQVIA by 9.0% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company's stock valued at $315,772,000 after purchasing an additional 134,997 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of IQVIA in the second quarter worth about $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of IQVIA by 8.3% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company's stock worth $209,057,000 after purchasing an additional 93,779 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.
IQVIA Price Performance
IQV opened at $271.45 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.83 and a debt-to-equity ratio of 2.18. The firm has a market cap of $44.74 billion, a price-to-earnings ratio of 32.98, a PEG ratio of 2.30 and a beta of 1.16. The stock's 50-day moving average price is $266.55 and its 200 day moving average price is $211.03. IQVIA has a 12-month low of $154.50 and a 12-month high of $284.50.
IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.26 by $0.08. The business had revenue of $4.43 billion for the quarter, compared to analysts' expectations of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business's quarterly revenue was up 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $3.00 EPS. As a group, sell-side analysts expect that IQVIA will post 11.53 earnings per share for the current year.
IQVIA Company Profile
(
Get Free Report)
IQVIA Holdings Inc provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products.
The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.